ALEPH-FARMS
16.3.2022 13:03:30 CET | Business Wire | Press release
Aleph Farms , the first company to grow cultivated beef steaks, today announced it is expanding its product line to include a unique platform for cell-cultured collagen production. The company’s highly differentiated, integrated strategy to develop a complete alternative to animals in intensive animal farming is a testament to its inclusive vision to supplement sustainable, but less productive, livestock agriculture practices.
“The cellular agriculture industry has made greater promises to replace a large part of intensive animal farming practices, which make up to 70% of the global meat production. Cultivated meat, however, is only part of that solution as meat represents just 30-35% of the cow that is slaughtered. The rest include many other valuable by-products. To achieve our vision, we need to provide alternatives to the other animal parts as well, including collagen-based products,” said Didier Toubia, co-founder and CEO of Aleph Farms. “Focusing on single categories of animal products does not account for the complexity of the animal agriculture ecosystem. The protein transition should rely on a systems-based approach to successfully contribute to a comprehensive, just and inclusive transition for animal agriculture.”
Conventional collagen is produced by boiling and processing cow’s hides and bones, and is widely used in a range of industries. Aleph Farms' cultivated collagen offers attributes of natural animal-based collagen that are unmatched by plant or fermented recombinant-based alternatives.
Aleph Frontiers is a division of Aleph Farms’ research center focused on the development of new technologies and products for eventual commercialization. As the first product to emerge from the company’s newly revealed incubator, and following 18 months of research by an expert team in stealth mode, Aleph’s collagen is now moving to full product development stage and should launch in 2024.
“We are leveraging key components from our production method for steaks—including our bovine cell sources and animal component-free growth medium—to produce several nature-identical collagen types directly from cow cells, as well as the entire extracellular matrix (ECM) which comprises a variety of fiber-forming proteins and represents the complete matrix of skin, bones and joints,” said Dr. Neta Lavon, CTO and VP of R&D at Aleph Farms. “Collagen is the most abundant protein in the ECM and is well recognized for its benefits.”
This announcement follows the company’s expansion to its new cultured-beef steaks pilot production plant. Both platforms largely share similar inputs and equipment and present operational and cost-reduction synergies.
About Aleph Farms
Aleph Farms grows cultivated beef steaks, from non-genetically engineered cells, that are not immortalized, isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005177/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 08:01:00 CEST | Press release
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older -- Data simultaneously published in the New England Journal of Medicine -- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent p
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 08:00:00 CEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 08:00:00 CEST | Press release
AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To
Curatis Increases Revenue Growth Guidance for 202611.6.2026 07:00:00 CEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Dole Expands Year Two of Highly Successful Global Campaign With Minecraft Designed Towards Maximum Performance With New Pineapple-Focused Experience11.6.2026 07:00:00 CEST | Press release
Nutrition, hydration and energizing recipes among tips for peak gameplay Following the global success of its first healthy gaming collaboration, Dole Food Company today announced the launch of the next phase of its partnership with Minecraft, expanding the campaign with new content, experiences and a fresh focus on pineapple in connection with Dole’s 125-year pineapple heritage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609035908/en/ Dole Food Company has launched a second phase of its popular healthy gaming collaboration with Minecraft with new content, experiences and a focus on pineapples. Launching June 21 and running through October 3, 2026, the campaign builds on Dole’s mission to Make the World a Healthier Place by helping families, gaming enthusiasts and younger audiences around the globe understand how nutritious foods can fuel energy, focus and performance—both on screen and in everyday life. The new campai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
